[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337111-105":59,"doc-detail-337111-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","dual-rectification-of-metabolism-abnormality-in-pancreatic-cancer-by-a-programmed-nanomedicine","Dual rectification of metabolism abnormality in pancreatic cancer by a programmed nanomedicine","","Pancreatic ductal adenocarcinoma (PDAC) is driven by dysregulated energy and stromal metabolism, with pancreatic stellate cells (PSC) promoting desmoplasia and tumor growth through metabolic crosstalk. A programmed nanosystem is designed to dual rectify PDAC-associated metabolism by targeting PDAC cells and PSC. The liposome co-delivers an NF-κB inhibitor (TPCA-1) and a CD71 aptamer-linked Glut1 siRNA, reversing PSC activation and suppressing glycolysis while enhancing oxidative phosphorylation. In an orthotopic xenograft mouse model, nano-modulation amplifies anti-PDAC efficacy and suggests more personalized treatment based on energy metabolic profiles.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dual-rectification-of-metabolism-abnormality-in-pancreatic-cancer-by-a-programmed-nanomedicine/337111/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dual-rectification-of-metabolism-abnormality-in-pancreatic-cancer-by-a-programmed-nanomedicine/337111.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is metabolic abnormality important in pancreatic ductal adenocarcinoma (PDAC)?","Question",{"text":112,"@type":113},"PDAC mortality is linked to metabolic disturbances across glucose, lipids, and amino acids. PDAC cells show altered energy metabolism, including enhanced glycolysis and metabolic crosstalk with the tumor microenvironment that supports growth and progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role do pancreatic stellate cells (PSC) play in PDAC progression?",{"text":117,"@type":113},"Activated PSC comprise a large fraction of the stromal compartment and contribute to metabolic imbalances. Their dense extracellular matrix affects delivery and hypoxia, while PSC–PDAC metabolic interactions facilitate tumor support.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the programmed nanomedicine address both PDAC and PSC metabolism?",{"text":121,"@type":113},"The nanosystem uses an NF-κB inhibitor (TPCA-1) to reverse activated PSC toward quiescence, disrupting metabolic support to PDAC cells. It also delivers CD71 aptamer-linked Glut1 siRNA to enhance PDAC-targeting delivery, restraining aerobic glycolysis and boosting oxidative phosphorylation to improve anti-PDAC efficacy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337111,1790137630,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Article [https://doi.org/10.1038/s41467-024-54963-y](https://doi.org/10.1038/s41467-024-54963-y)  \nDual rectiﬁcation of metabolism abnormality in pancreatic cancer by a programmed nanomedicine  \nReceived: 28 December 2023  \n\n| Accepted: 19 November 2024 |\n| --- |\n| |\n| Check for updates |\n\nBowen Wu1,2,3,6, Zhiqin Wang2,4,6, Jingyuan Liu2, Naishi Li2, Xudong Wang2, HaoChen Bai2, Chunling Wang2, Jian Shi2, Saiyang Zhang1, Jian Song1, Yiye Li 2,5  & Guangjun Nie 1,2,3,5   \nPancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and lethal malignancy characterized by dysregulated energy and stromal metabolism. It is strongly supported by activated pancreatic stellate cells (PSC) which drive excessive desmoplasia and tumor growth via metabolic crosstalk. Herein, a programmed nanosystem is designed to dual rectify the metabolism abnormalities of the PDAC cells, which overexpress glucose transporter 1(GLUT1) and CD71, and the PSC for oncotherapy. The nanosystem is based on a tumor microenvironment-responsive liposome encapsulating an NF-κB inhibitor (TPCA-1) and a CD71 aptamer-linked Glut1 siRNA. TPCA-1 reverses the activated PSC to quiescence, which hampers metabolic support of the PSC to PDAC cells and bolsters the PDAC cell-targeting delivery of the siRNA. Aerobic glycolysis and the following enhancement of oxidative phosphorylation are restrained by the nano-modulation so as to amplify anti-PDAC efﬁcacy in an orthotopic xenograft mouse model, which implies more personalized PDAC treatment based on different energy metabolic proﬁles.  \nPancreatic ductal adenocarcinoma (PDAC) is predicted to become the third primary cause of cancer-related mortality by 2025 due to its insidious onset, early distal metastasis, and dismal prognosis1,2. Metabolic disturbances of glucose, lipids, amino acids, etc., are signiﬁcant contributors to this high mortality rate and major factors behind the disappointing outcomes of clinical trials targeting PDAC3,4. PDAC cells exhibit altered energy metabolism patterns, such as enhanced glycolysis, even in the presence of oxygen, a phenomenon known as the Warburg effect5. This metabolic shift supports the high energy demands of rapidly proliferating cancer cells, further interlinking with cancer hallmarks such as treatment resistance, metastasis, and invasion6. PDAC cells also extensively promote the metabolic rearrangement of non-cancer cells in the tumor microenvironment (TME)  \nfor nutrition support, clearance of metabolic waste, and immune escape so as to facilitate their growth and survival7,8. Efforts to target these metabolic aberrations in PDAC are being explored as potential therapeutic strategies.  \nActivated pancreatic stellate cell (PSC), the main stromal cell of PDAC, accounts for 50% of the stroma and is comprehensively implicated in PDAC metabolic imbalances, including reprogramming of stroma and energy metabolism9. The dense extracellular matrix (ECM) excessively secreted by PSC creates a physical hurdle that contributes to increased interstitial ﬂuid pressure10, impaired hemoperfusion11, cellular hypoxia12, and blockage of nutrient and drug delivery13. Furthermore, metabolic interaction between PSC and PDAC cells is a crucial factor in PDAC progression14. PSC activated by PDAC cells  \n1School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, PR China. 2CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, PR China. 3Henan Institute of Advanced Technology, Henan, PR China. 4College of Pharmaceutical Science, Jilin University, Changchun, PR China. 5College of Materials Science and Opto-Electronic Technology, University of Chinese Academy of Sciences, Beijing, PR China. 6These authors contributed equally: Bowen Wu, Zhiqin Wang.  \ne-mail: [liyy@nanoctr.cn](liyy@nanoctr.cn); [niegj@nanoctr.cn](niegj@nanoctr.cn)  \nrewrite its metabolic proﬁle as aerobic glycolysis,","cbCailTfAR2FlqMH","https://ap.wps.com/l/cbCailTfAR2FlqMH","pdf",5440576,"English","# Introduction\n## PDAC and metabolic dysregulation\n## Tumor microenvironment and PSC-driven metabolism\n## NF-κB as a metabolic regulator\n# Programmed nanosystem design\n## TME/PDAC sequential targeting concept","[{\"question\":\"Why is metabolic abnormality important in pancreatic ductal adenocarcinoma (PDAC)?\",\"answer\":\"PDAC mortality is linked to metabolic disturbances across glucose, lipids, and amino acids. PDAC cells show altered energy metabolism, including enhanced glycolysis and metabolic crosstalk with the tumor microenvironment that supports growth and progression.\"},{\"question\":\"What role do pancreatic stellate cells (PSC) play in PDAC progression?\",\"answer\":\"Activated PSC comprise a large fraction of the stromal compartment and contribute to metabolic imbalances. Their dense extracellular matrix affects delivery and hypoxia, while PSC–PDAC metabolic interactions facilitate tumor support.\"},{\"question\":\"How does the programmed nanomedicine address both PDAC and PSC metabolism?\",\"answer\":\"The nanosystem uses an NF-κB inhibitor (TPCA-1) to reverse activated PSC toward quiescence, disrupting metabolic support to PDAC cells. It also delivers CD71 aptamer-linked Glut1 siRNA to enhance PDAC-targeting delivery, restraining aerobic glycolysis and boosting oxidative phosphorylation to improve anti-PDAC efficacy.\"}]","Dual rectification of metabolism abnormality in pancreatic cancer by a programmed nanomedicine | PDF",1790017735,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46c2dd851bcd175eb2911401e48f3f8b.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50bbf6ac1d447b11e910e4d15f9c73e7.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4aa8d66caac44e745a3861dd2e5167f.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8bd34f091ba98b49eeefd9a2bd68d6f.webp",980,1301]